CurrentKaiser PermanentePolicy N/A

Prolotherapy / Sclerotherapy (Proliferative Injection Therapy) Coverage Criteria

Defines Kaiser Permanente Washington coverage stance and clinical review findings for prolotherapy/sclerotherapy for musculoskeletal indications, including low back pain; applies to Kaiser Foundation Health Plan of Washington members and providers.

Policy Summary

PayerKaiser Permanente

PolicyProlotherapy / Sclerotherapy (Proliferative Injection Therapy) Coverage Criteria

Policy CodePolicy N/A

Change TypeAdded evidence review (Hayes)

Effective DateN/A

Next Review DateN/A

Key ActionDo not request authorization for prolotherapy (M0076); the service is considered not medically necessary for non‑Medicare members.

SourceLink

POLICY UPDATE CHANGES

Added Hayes Technology Assessment Evidence Review.

Not Medically NecessaryCoverage stance for prolotherapy

1999, 2002MTAC reviews referenced

through Mar 2008Hayes assessment timeframe

5–8Trials evaluated

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Medically Necessary / Insufficient Evidence

Coverage stance and rationale

Primary coverage determination: Prolotherapy/sclerotherapy is considered not medically necessary for ANY indication for non‑Medicare members due to insufficient evidence of efficacy and methodological limitations of available trials.

Supported by MTAC reviews (1999, 2002) and a Hayes Technology Assessment finding inconsistent results, methodological weaknesses, and inability to isolate the effect of prolotherapy from concomitant therapies.

The policy lists contraindications for prolotherapy/sclerotherapy that mirror those identified in the Hayes Technology Assessment. Contraindications include: metastatic cancer, nonmusculoskeletal pain, spinal anatomical defects, systemic inflammation, morbid obesity, bleeding disorders, low pain threshold, inability to perform post‑treatment exercises, whole body pain, and hepatic conditions.

Prolotherapy/sclerotherapy is considered not medically necessary for the treatment of low back pain and for treatment of other indications involving joint or ligament instability. Internal MTAC reviews and external technology assessments found the randomized trials to be methodologically limited, inconsistent in results, and often confounded by concomitant interventions, such that the effect of prolotherapy alone has not been established.

Provider Requirements and Actions

Prior Authorization

Prior Authorization Stance — Prolotherapy

Prior authorization is not supported for prolotherapy (HCPCS code M0076). Prolotherapy is considered Not Medically Necessary for all indications; do not submit prior authorization requests expecting approval.

Affected code: M0076 — Prolotherapy
Note: Codes may not be all-inclusive; deleted or out-of-effect codes may not be covered

Note

Conservative Treatments (Background)

Conservative care is the recommended baseline management for musculoskeletal back pain before considering invasive or injectable therapies. Common conservative treatments include physical therapy, nonsteroidal and steroidal anti-inflammatory medications, chiropractic manipulation, and other noninvasive symptomatic therapies. Prolotherapy (sclerotherapy) — injection of irritant solutions intended to induce local inflammation and collagen deposition — lacks sufficient evidence demonstrating safety and superior long-term outcomes compared with standard conservative treatments.

Note

Verify Member Benefits

Always verify member-specific benefits and coverage by consulting the member's Evidence of Coverage or contacting Kaiser Permanente Member Services.

Check Evidence of Coverage for plan-specific exclusions or limits
Contact Member Services to confirm coverage prior to scheduling services

Denial Risk

Denial Risk for Prolotherapy

For non‑Medicare members, prolotherapy/sclerotherapy is considered Not Medically Necessary for any indication; submitting claims for this service may result in denial.

Denial risk applies to HCPCS code M0076
Use Pre-authorization Code Check to validate any plan-specific rules

Background and Scope

Prolotherapy (also called sclerotherapy or proliferative injection therapy) refers to the injection of sclerosing or irritant solutions into fibro‑osseous junctions and soft tissues with the intent of inducing localized inflammation and collagen deposition to strengthen ligaments and tendons. The procedure has been used for chronic low back pain and other musculoskeletal complaints, but systematic reviews and technology assessments have found evidence insufficient to reliably demonstrate benefit over placebo or standard therapies.

Key Definitions

Definition — Prolotherapy / Sclerotherapy

TermProlotherapy / Sclerotherapy (proliferative injection therapy)

DefinitionInjection of sclerosing or irritant compounds into soft tissues (eg, fibro‑osseous junctions) to induce local inflammation, scarring, collagen deposition, and potential stabilization of ligaments/tendons.

SynonymsSclerotherapy; Proliferative injection therapy

Typical indication described in policyUsed historically for chronic low back pain and other musculoskeletal complaints resistant to conservative treatments.

Mechanism of action (rationale)Irritant injections provoke a wound‑healing inflammatory cascade leading to new collagen deposition and stronger ligaments, with intended stabilization of the injured area.